Fresenius Establishes Over €200 Million Venture Fund for Healthcare Innovation

Fresenius SE & Co. KGaA, a global healthcare company, has launched Fresenius Ventures, a corporate venture capital fund aimed at driving innovation within the healthcare sector. The fund has an intended investment volume exceeding €200 million over the next five years.

Fresenius Ventures will focus on investing in founders, technologies, and business models from early financing rounds through to the growth stage. The newly formed unit combines venture capital expertise with medical, regulatory, and operational knowledge, providing portfolio companies access to Fresenius' extensive clinical, scientific, and academic networks.

The fund's investment strategy will concentrate on growth fields that complement Fresenius' current strategic platforms, including (bio)pharmaceuticals, medical technology (MedTech), and care provision. Specific areas of interest may encompass precision nutrition, microbiome research, novel therapeutic modalities, and digital care solutions.

Michael Sen, CEO of Fresenius, stated that Fresenius Ventures is a strategic instrument to gain early access to breakthrough technologies and entrepreneurial talent. He highlighted that this initiative will strengthen the company's innovation capabilities within the broader healthcare ecosystem and tap into adjacent growth areas. Dr. Thomas Michael Thestrup, an experienced healthcare and corporate venture capital expert, has been appointed to lead Fresenius Ventures.